Welcome to our dedicated page for Stoke Therapeutics SEC filings (Ticker: STOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stoke Therapeutics filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing RNA medicines, including zorevunersen for Dravet syndrome. Recent 8-K reports cover quarterly financial results, clinical-program updates, capital resources, material agreements, lease obligations, board appointments, executive compensation, auditor changes, and Regulation FD disclosures.
The company’s definitive proxy materials describe annual meeting voting matters, director elections, board committee structure, governance practices, equity compensation, and related stockholder information. Filings also identify its common stock registered on the Nasdaq Global Select Market under STOK.
Stoke Therapeutics, Inc. reported insider equity transactions by a company director. On December 3, 2025, the director exercised 26,250 performance stock units at an exercise price of $0, receiving an equal number of common shares. On December 4 and 5, 2025, portions of these and other shares were sold in several market transactions at weighted average prices ranging from $30.23 to $31.96 per share.
One sale on December 4, 2025 is described as an issuer-mandated sale to cover tax withholding tied to the vesting and settlement of restricted stock units. Additional sales on December 5, 2025 were executed under a Rule 10b5-1 trading plan adopted on December 30, 2024. After all reported transactions, the director directly holds 62,554 shares of Stoke Therapeutics common stock, and no performance stock units remain from the reported award. The underlying award vested in two equal parts on December 3, 2024 and December 3, 2025.
Stoke Therapeutics, Inc. (STOK) director reported an open-market sale of company stock. On 11/24/2025, the reporting person sold 40,472 shares of common stock at a weighted average price of $29.7173 per share, through multiple transactions within a price range of $29.50 to $30.12. After this sale, the director beneficially owned 323,774 shares of Stoke Therapeutics common stock in direct ownership form. The filing notes that the sale was made under a Rule 10b5-1 trading plan that was adopted on August 15, 2025.
Stoke Therapeutics, Inc.$26.6141 per share and 20,682 shares at a weighted average price of $27.3361 per share, in each case coded as an open market sale. After these transactions, the director beneficially owned 364,246 shares of Stoke Therapeutics common stock in direct form.
The filing states that the trades were executed under a Rule 10b5-1 trading plan adopted on August 15, 2025, which is designed to provide an affirmative defense for pre-arranged trading. The prices reported reflect multiple individual trades within stated price ranges, and the reporting person has agreed to provide detailed breakdowns of the prices upon request.
Stoke Therapeutics (STOK) disclosed insider sales by its Chief Medical Officer on 11/03/2025 under a pre‑arranged Rule 10b5-1 trading plan adopted on December 11, 2024. The transactions included 3,776 shares at a weighted average price of $25.2242 (range $24.74–$25.65), 1,455 shares at $26.0206 (range $25.79–$26.50), 600 shares at $27.54 (range $27.40–$27.60), and 100 shares at $29.35.
Following these sales, the reporting person directly beneficially owned 7,195 shares.
Stoke Therapeutics reported Q3 2025 results. Revenue was $10.6 million versus $4.9 million a year ago, with a net loss of $38.3 million (basic and diluted EPS of $0.65 loss). For the first nine months, revenue rose to $183.0 million and net income reached $51.0 million (diluted EPS $0.85), driven primarily by collaboration revenue.
Cash, cash equivalents and marketable securities totaled $328.6 million as of September 30, 2025. Stockholders’ equity increased to $308.1 million. The company recorded $150.8 million of license revenue and $11.5 million of development revenue year-to-date under its Biogen collaboration, following a $165.0 million upfront payment and 70/30 cost sharing. Deferred revenue was $14.3 million (current and long-term combined). The Phase 3 EMPEROR study of zorevunersen began in May 2025, with first patient dosed in August 2025.
After quarter-end, the company sold approximately 1.8 million shares for $48.7 million in net proceeds. Shares outstanding were 57,117,150 as of October 31, 2025.
Stoke Therapeutics, Inc. (STOK) filed an 8-K noting it issued a press release announcing financial results for the quarter ended September 30, 2025. The filing lists the press release as Exhibit 99.1 and identifies the company’s common stock as trading on the Nasdaq Global Select Market. This is a routine disclosure of quarterly results via press release.
Stoke Therapeutics (STOK) reported insider equity grants to its Chief Executive Officer and Director. On 10/08/2025, the reporting person received a stock option to buy 570,000 shares at $30.5 per share, expiring on 10/07/2035. The option vests as to 1/4 on 10/06/2026, then 1/48 monthly thereafter, subject to continued service.
The filing also reports 380,000 RSUs, each representing one share of common stock, vesting 1/4 annually on the sixth day of October, with the first tranche on 10/06/2026, subject to continued service. Ownership form for both awards is listed as direct.
Stoke Therapeutics director Edward M. Kaye reported transactions under a Rule 10b5-1 plan dated 12/30/2024. On 10/08/2025 he exercised a stock option with a $0.6 exercise price to acquire 25,000 shares and simultaneously sold 25,000 shares at $30 per share, leaving him with 49,124 shares beneficially owned. The option is fully vested; original vesting began on 10/17/2018 with monthly vesting thereafter, and the reporting was authorized by an attorney-in-fact on 10/10/2025. The filing indicates these actions were made pursuant to the 10b5-1 trading plan to satisfy the affirmative defense conditions.
Stoke Therapeutics (STOK) filed a Rule 144 notice for a proposed sale of 25,000 common shares acquired by an exercise of stock options on 10/08/2025. The shares are to be sold through Morgan Stanley Smith Barney LLC with an aggregate market value of $682,750 against 54,797,418 shares outstanding, indicating the block is a very small portion of the float. The filing shows the option exercise and cash payment both occurred on 10/08/2025, and the seller certifies no undisclosed material nonpublic information.
Related trading history lists 116,472 shares sold in the past three months by the same named insider, generating gross proceeds of $2,532,056.28, executed under a mix of 10b5-1 program and direct sales. These prior disposals and the new Rule 144 notice document routine insider liquidity rather than company operational changes.
Director Edward M. Kaye reported the sale of 42,461 shares of Stoke Therapeutics common stock on 10/03/2025 under a pre-existing Rule 10b5-1 trading plan. The filing shows a weighted-average sale price of $25.0867 (individual trades ranged from $25.00 to $25.30), leaving the reporting person with 49,124 shares beneficially owned after the transactions. The schedule was signed by an attorney-in-fact on 10/07/2025.